Pharmaceuticals Stocks

Perrigo Company PLC Valuation – April 2018 $PRGO

Company Profile (excerpt from Reuters): Perrigo Company PLC (Perrigo), formerly Perrigo Company Limited, incorporated on June 28, 2013, is an over-the-counter (OTC) consumer goods and specialty pharmaceutical company. The Company’s segments include Consumer Healthcare (CHC), Branded Consumer Healthcare (BCH), Prescription Pharmaceuticals (Rx) and Specialty Sciences. The Company manufactures OTC healthcare products and supplies infant formulas for the store brand market. It is also a provider of generic extended topical prescription products. It provides healthcare products across a range of product categories and geographies, primarily in North America, Europe and Australia, as well as in other markets, including Israel and China.

PRGO Chart

PRGO data by YCharts

 

Downloadable PDF version of this valuation:

ModernGraham Valuation of PRGO – April 2018

Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

What kind of Intelligent Investor are you?

Defensive Investor; must pass 6 out of the following 7 tests.
1. Adequate Size of the Enterprise Market Cap > $2Bil $11,747,554,100 Pass
2. Sufficiently Strong Financial Condition Current Ratio > 2 1.96 Fail
3. Earnings Stability Positive EPS for 10 years prior Fail
4. Dividend Record Dividend Payments for 10 years prior Pass
5. Earnings Growth Increase of 33% in EPS in past 10 years using 3 year averages at beginning and end -391.56% Fail
6. Moderate PEmg Ratio PEmg < 20 -24.45 Fail
7. Moderate Price to Assets PB Ratio < 2.5 OR PB*PEmg < 50 1.93 Fail
Enterprising Investor; must pass 4 out of the following 5 tests, or be suitable for the Defensive Investor.
1. Sufficiently Strong Financial Condition Current Ratio > 1.5 1.96 Pass
2. Sufficiently Strong Financial Condition Debt to NCA < 1.1 2.36 Fail
3. Earnings Stability Positive EPS for 5 years prior Fail
4. Dividend Record Currently Pays Dividend Pass
5. Earnings Growth EPSmg greater than 5 years ago Fail

 

Stage 2: Determination of Intrinsic Value

EPSmg -$3.42
MG Growth Estimate -4.25%
MG Value $0.00
Opinion Overvalued
MG Grade D
MG Value based on 3% Growth -$49.66
MG Value based on 0% Growth -$29.11
Market Implied Growth Rate -16.47%
Current Price $83.72
% of Intrinsic Value N/A

Perrigo Company plc Ordinary Shares does not satisfy the requirements of either the Enterprising Investor or the more conservative Defensive Investor. The Defensive Investor is concerned with the low current ratio, insufficient earnings stability or growth over the last ten years, and the high PEmg and PB ratios. The Enterprising Investor has concerns regarding the level of debt relative to the net current assets, and the lack of earnings stability or growth over the last five years. As a result, all value investors following the ModernGraham approach should explore other opportunities at this time or proceed cautiously with a speculative attitude.

As for a valuation, the company appears to be Overvalued after seeing its EPSmg (normalized earnings) decline from $3.42 in 2014 to an estimated $-3.42 for 2018. This level of negative earnings does not support a positive valuation.As a result, the ModernGraham valuation model, based on the Benjamin Graham value investing formula, returns an estimate of intrinsic value below the price.

At the time of valuation, further research into Perrigo Company plc Ordinary Shares revealed the company was trading above its Graham Number of $70.71. The company pays a dividend of $0.64 per share, for a yield of 0.8% Its PEmg (price over earnings per share – ModernGraham) was -24.45, which was below the industry average of 29.14, which by some methods of valuation makes it one of the most undervalued stocks in its industry. Finally, the company was trading above its Net Current Asset Value (NCAV) of $-18.58.

Perrigo Company plc Ordinary Shares scores quite poorly in the ModernGraham grading system, with an overall grade of D.

Stage 3: Information for Further Research

Net Current Asset Value (NCAV) -$18.58
Graham Number $70.71
PEmg -24.45
Current Ratio 1.96
PB Ratio 1.93
Current Dividend $0.64
Dividend Yield 0.76%
Number of Consecutive Years of Dividend Growth 15

Useful Links:

ModernGraham tagged articles Morningstar
Google Finance MSN Money
Yahoo Finance Seeking Alpha
GuruFocus SEC Filings

Most Recent Balance Sheet Figures

Balance Sheet Information 12/1/2017
Total Current Assets $2,819,600,000
Total Current Liabilities $1,436,000,000
Long-Term Debt $3,270,800,000
Total Assets $11,628,800,000
Intangible Assets $7,556,200,000
Total Liabilities $5,458,300,000
Shares Outstanding (Diluted Average) 142,000,000

Earnings Per Share History

EPS History
Next Fiscal Year Estimate $5.07
Dec2017 $0.84
Dec2016 -$28.01
Jun2015 $0.97
Jun2014 $2.01
Jun2013 $4.68
Jun2012 $4.27
Jun2011 $3.63
Jun2010 $2.41
Jun2009 $1.54
Jun2008 $1.43
Jun2007 $0.79
Jun2006 $0.76
Jun2005 -$4.57
Jun2004 $1.11
Jun2003 $0.76
Jun2002 $0.60
Jun2001 $0.33
Jun2000 $0.23
Jun1999 $0.02
Jun1998 -$0.69

Earnings Per Share – ModernGraham History

EPSmg History
Next Fiscal Year Estimate -$3.42
Dec2017 -$6.42
Dec2016 -$7.77
Jun2015 $2.61
Jun2014 $3.42
Jun2013 $3.85
Jun2012 $3.17
Jun2011 $2.40
Jun2010 $1.66
Jun2009 $0.85
Jun2008 $0.30
Jun2007 -$0.25
Jun2006 -$0.60
Jun2005 -$0.97
Jun2004 $0.75
Jun2003 $0.51
Jun2002 $0.29

Recommended Reading:

Other ModernGraham posts about the company

Perrigo Co PLC Valuation – January 2016 Update $PRGO
Perrigo Company PLC Analysis – October 2015 Update $PRGO
Perrigo Company Analysis – July 2015 Update $PRGO
24 Companies in the Spotlight This Week – 3/28/15
Perrigo Company plc Quarterly Valuation – March 2015 $PRGO

Other ModernGraham posts about related companies

AbbVie Inc Valuation – April 2018 $ABBV
Eli Lilly and Co. Valuation – March 2018 $LLY
Zoetis Inc Valuation – March 2018 $ZTS
Gilead Sciences Inc Valuation – March 2018 $GILD
Pfizer Inc Valuation – February 2018 $PFE
Merck & Co Inc Valuation – February 2018 $MRK
Johnson & Johnson Valuation – February 2018 $JNJ
Bristol-Myers Squibb Co Valuation – September 2017 $BMY
Momenta Pharmaceuticals Inc Valuation – Initial Coverage $MNTA
Depomed Inc Valuation – Initial Coverage $DEPO

Disclaimer:

The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing that position within the next 72 hours.  See my current holdings here.  This article is not investment advice; any reader should speak to a registered investment adviser prior to making any investment decisions.  ModernGraham is not affiliated with the company in any manner.  Please be sure to review our detailed disclaimer.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Back To Top